Regulation of 11Î²â€HSD Genes in Human Adipos Weight Loss

Obesity

12, 9-17

DOI: 10.1038/oby.2004.3

Citation Report

#	Article	IF	Citations
1	Obesity-Initiated Metabolic Syndrome and the Kidney: A Recipe for Chronic Kidney Disease?. Journal of the American Society of Nephrology: JASN, 2004, 15, 2775-2791.	3.0	219
2	Glucocorticoids contribute to the heritability of leptin in Scottish adult female twins. Clinical Endocrinology, 2004, 61, 149-154.	1.2	4
3	11Î²â€Hydroxysteroid Dehydrogenase Type 1 in Obesity. Obesity, 2004, 12, 1-3.	4.0	27
4	Current and Investigational Antiobesity Agents and Obesity Therapeutic Treatment Targets. Obesity, 2004, 12, 1197-1211.	4.0	193
5	Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutrition and Metabolism, 2004, 1, 12.	1.3	224
6	Mapping and association studies of diabetes related genes in the pig. Animal Genetics, 2005, 36, 36-42.	0.6	21
7	In vivo activity of 11beta-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance. Clinical Endocrinology, 2005, 63, 442-449.	1.2	12
9	Increased uncoupling protein-2 mRNA abundance and glucocorticoid action in adipose tissue in the sheep fetus during late gestation is dependent on plasma cortisol and triiodothyronine. Journal of Physiology, 2005, 567, 283-292.	1.3	16
10	Regulation of 11Î²-hydroxysteroid dehydrogenase type 1 and glucose-stimulated insulin secretion in pancreatic islets of Langerhans. Diabetes/Metabolism Research and Reviews, 2005, 21, 359-366.	1.7	23
11	Maternal nutritional programming of fetal adipose tissue development: Long-term consequences for later obesity. Birth Defects Research Part C: Embryo Today Reviews, 2005, 75, 193-199.	3.6	76
12	Ontogeny and nutritional programming of adiposity in sheep: potential role of glucocorticoid action and uncoupling protein-2. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 289, R1407-R1415.	0.9	94
13	11Î²-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. Journal of Experimental Medicine, 2005, 202, 517-527.	4.2	353
14	The Contribution of Visceral Adipose Tissue to Splanchnic Cortisol Production in Healthy Humans. Diabetes, 2005, 54, 1364-1370.	0.3	93
15	Reduced Adipose Glucocorticoid Reactivation and Increased Hepatic Glucocorticoid Clearance as an Early Adaptation to High-Fat Feeding in Wistar Rats. Endocrinology, 2005, 146, 913-919.	1.4	69
16	Inhibition of 11Î²-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?. Expert Review of Cardiovascular Therapy, 2005, 3, 911-924.	0.6	45
17	Conformational Flexibility in Crystal Structures of Human 11Î²-Hydroxysteroid Dehydrogenase Type I Provide Insights into Glucocorticoid Interconversion and Enzyme Regulation. Journal of Biological Chemistry, 2005, 280, 4639-4648.	1.6	99
18	Adipocyte-Specific Glucocorticoid Inactivation Protects Against Diet-Induced Obesity. Diabetes, 2005, 54, 1023-1031.	0.3	235
19	Increased In Vivo Regeneration of Cortisol in Adipose Tissue in Human Obesity and Effects of the 11Â-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Carbenoxolone. Diabetes, 2005, 54, 872-879.	0.3	179

#	Article	IF	Citations
20	The Metabolic Syndrome and Cardiovascular Risk in Cushing's Syndrome. Endocrinology and Metabolism Clinics of North America, 2005, 34, 327-339.	1.2	146
21	Inhibition of 11Î²-Hydroxysteroid Dehydrogenase Type 1 in Obesity. Endocrine, 2006, 29, 101-108.	2.2	31
22	Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. Expert Review of Cardiovascular Therapy, 2006, 4, 871-895.	0.6	89
23	Cortisol?cause and cure for metabolic syndrome?. Diabetic Medicine, 2006, 23, 1281-1288.	1.2	154
24	Role of 11-beta-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3-L1 cells and in rats with diet-induced obesity1. Acta Pharmacologica Sinica, 2006, 27, 588-596.	2.8	13
25	Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clinical Endocrinology, 2006, 65, 81-87.	1.2	65
26	11Î²â€Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue and Prospective Changes in Body Weight and Insulin Resistance. Obesity, 2006, 14, 1515-1522.	1.5	19
27	11Î²â€Hydroxysteroid Dehydrogenase Type 1 mRNA is Increased in Both Visceral and Subcutaneous Adipose Tissue of Obese Patients. Obesity, 2006, 14, 794-798.	1.5	153
28	LipotoxicitÃ© etÂinsulinorÃ©sistance. Nutrition Clinique Et Metabolisme, 2006, 20, 108-113.	0.2	3
29	Tissue Production of Cortisol by 11beta-Hydroxysteroid Dehydrogenase Type 1 and Metabolic Disease. Annals of the New York Academy of Sciences, 2006, 1083, 165-184.	1.8	121
30	Comparison of a homology model and the crystallographic structure of human 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD1) in a structure-based identification of inhibitors. Journal of Computer-Aided Molecular Design, 2006, 20, 67-81.	1.3	20
31	Enhanced 11Î²-Hydroxysteroid Dehydrogenase Activity, the Metabolic Syndrome, and Systemic Hypertension. American Journal of Cardiology, 2006, 98, 544-548.	0.7	24
32	Acute In Vivo Regulation of 11Î²-Hydroxysteroid Dehydrogenase Type 1 Activity by Insulin and Intralipid Infusions in Humans. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4682-4688.	1.8	52
33	Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovascular Research, 2006, 71, 363-373.	1.8	193
34	Evidence That the 11 Î²-Hydroxysteroid Dehydrogenase (11 Î²-HSD1) Is Regulated by Pentose Pathway Flux. Journal of Biological Chemistry, 2006, 281, 341-347.	1.6	63
35	Adipose tissue 11Î²-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushingâ€™s syndrome. European Journal of Endocrinology, 2006, 155, 435-441.	1.9	67
36	Dietary Macronutrient Content Alters Cortisol Metabolism Independently of Body Weight Changes in Obese Men. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4480-4484.	1.8	71
37	Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. Biochemical Journal, 2007, 402, 419-427.	1.7	79

#	Article	IF	Citations
38	Free fatty acids and insulin resistance. Current Opinion in Clinical Nutrition and Metabolic Care, 2007, 10, 142-148.	1.3	369
39	Extra-adrenal regeneration of glucocorticoids by 11Î²-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning. Proceedings of the Nutrition Society, 2007, 66, 1-8.	0.4	43
40	GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women. Regulatory Peptides, 2007, 142, 138-145.	1.9	47
41	11-Î² Hydroxysteroid dehydrogenase type 2 expression in white adipose tissue is strongly correlated with adiposity. Journal of Steroid Biochemistry and Molecular Biology, 2007, 104, 81-84.	1.2	41
42	Angiotensin II, corticosteroids, type II diabetes and the metabolic syndrome. Medical Hypotheses, 2007, 68, 1200-1207.	0.8	14
43	Cell-type specific regulation of the human 11beta-hydroxysteroid dehydrogenase type 1 promoter. Archives of Physiology and Biochemistry, 2007, 113, 110-115.	1.0	3
44	Glucocorticoids and Cardiovascular Disease. European Journal of Endocrinology, 2007, 157, 545-559.	1.9	446
45	The Adipocyte as an Active Participant in Energy Balance and Metabolism. Gastroenterology, 2007, 132, 2103-2115.	0.6	228
48	Adipose tissue expression of 11beta-Hydroxysteroid dehydrogenase type 1 in cushing's syndrome and in obesity. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1397-1403.	1.3	21
49	Effects of Gonadectomy on Glucocorticoid Metabolism in Obese Zucker Rats. Endocrinology, 2007, 148, 4836-4843.	1.4	16
50	Cushing's Syndrome and Human Glucocorticoid Hypertension. , 2007, , 835-864.		0
51	Depot-specific messenger RNA expression of 11Î²-hydroxysteroid dehydrogenase type 1 and leptin in adipose tissue of children and adults. International Journal of Obesity, 2007, 31, 820-828.	1.6	28
52	Type 2 diabetes and metabolic syndrome are associated with increased expression of 11Î²-hydroxysteroid dehydrogenase 1 in obese subjects. International Journal of Obesity, 2007, 31, 1826-1831.	1.6	59
53	11Î²â€HSD Type 1 Expression in Human Adipose Tissue: Impact of Gender, Obesity, and Fat Localization. Obesity, 2007, 15, 1954-1960.	1.5	122
54	Omental 11Î²â€hydroxysteroid Dehydrogenase 1 Correlates with Fat Cell Size Independently of Obesity. Obesity, 2007, 15, 1155-1163.	1.5	95
55	Rosiglitazone decreases 11?-hydroxysteroid dehydrogenase typeï¿½1 in subcutaneous adipose tissue. Clinical Endocrinology, 2007, 67, 419-425.	1.2	34
56	Losartan decreases vasopressinâ€mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure. Acta Physiologica, 2007, 190, 339-350.	1.8	13
57	11 beta-hydroxysteroid dehydrogenase type 1 promotes differentiation of 3T3-L1 preadipocyte. Acta Pharmacologica Sinica, 2007, 28, 1198-1204.	2.8	11

#	Article	IF	Citations
58	Inhibition of 11ÃŸ-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discovery Today, 2007, 12, 504-520.	3.2	148
59	Highâ€Cortisol States Can Masquerade as the Cardiometabolic Syndrome. Journal of the Cardiometabolic Syndrome, 2007, 2, 223-226.	1.7	0
60	Correlation of Obesity and Osteoporosis: Effect of Fat Mass on the Determination of Osteoporosis. Journal of Bone and Mineral Research, 2008, 23, 17-29.	3.1	408
61	Discovery and Metabolic Stabilization of Potent and Selective 2-Amino-N-(adamant-2-yl) Acetamide 11Î²-Hydroxysteroid Dehydrogenase Type 1 Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 149-164.	2.9	80
62	Lysophosphatidylcholine upregulates LOX-1, chemokine receptors, and activation-related transcription factors in human T-cell line Jurkat. Journal of Thrombosis and Thrombolysis, 2008, 26, 113-118.	1.0	18
63	Obesity, sleep apnea, aldosterone, and hypertension. Current Hypertension Reports, 2008, 10, 222-226.	1.5	37
64	Fat feeding potentiates the diabetogenic effect of dexamethasone in Wistar rats. International Archive of Medicine, 2008, 1, 7.	1.2	12
65	Type 2 diabetes: Gaining insight into the disease process using proteomics. Proteomics - Clinical Applications, 2008, 2, 312-326.	0.8	7
66	Upregulation of Adipose 11â€Î²â€Hydroxysteroid Dehydrogenase Type 1 Expression in Ovariectomized Rats Is due to Obesity Rather Than Lack of Estrogen. Obesity, 2008, 16, 731-735.	1.5	13
67	Depotâ€specific Regulation of the Conversion of Cortisone to Cortisol in Human Adipose Tissue. Obesity, 2008, 16, 1178-1185.	1.5	62
68	11-Beta-hydroxysteroid dehydrogenase type 1 (11Î²-HSD1) inhibitors in Type 2 diabetes mellitus and obesity. Expert Opinion on Investigational Drugs, 2008, 17, 481-496.	1.9	84
69	Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue. Metabolism: Clinical and Experimental, 2008, 57, 1005-1015.	1.5	61
70	11Î²-Hydroxysteroid Dehydrogenase Type 1 and Obesity. , 2007, , 175-196.		0
71	The biological roles of extracellular and intracytoplasmic glucocorticoids in skeletal cells. Journal of Steroid Biochemistry and Molecular Biology, 2008, 111, 164-170.	1.2	13
72	Tissue-specific glucocorticoid action: a family affair. Trends in Endocrinology and Metabolism, 2008, 19, 331-339.	3.1	169
73	Impact of visceral adipose tissue on liver metabolism. Diabetes and Metabolism, 2008, 34, 317-327.	1.4	114
74	11&Bgr;-Hydroxysteroid Dehydrogenase Type 1 and Obesity. , 2008, 36, 146-164.		117
75	Insulin and Dexamethasone Dynamically Regulate Adipocyte 11Î²-Hydroxysteroid Dehydrogenase Type 1. Endocrinology, 2008, 149, 4069-4079.	1.4	54

#	Article	IF	Citations
76	Glucocorticoid Regulation of the Promoter of 11Î²-Hydroxysteroid Dehydrogenase Type 1 Is Indirect and Requires CCAAT/Enhancer-Binding Protein-Î². Molecular Endocrinology, 2008, 22, 2049-2060.	3.7	75
77	Physiological roles of 11Î²-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase. Current Opinion in Pediatrics, 2008, 20, 453-457.	1.0	13
78	Reninâ€“angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. Journal of Hypertension, 2008, 26, 831-843.	0.3	236
79	Tissue-Specific Increases in 11Î²-Hydroxysteroid Dehydrogenase Type 1 in Normal Weight Postmenopausal Women. PLoS ONE, 2009, 4, e8475.	1.1	32
80	Enhanced cortisol production rates, free cortisol, and 11Î²-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E351-E357.	1.8	94
81	The pituitaryâ€“adrenal axis and body composition. Pituitary, 2009, 12, 105-115.	1.6	47
82	Expression of 11Î²-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome. International Journal of Obesity, 2009, 33, 1249-1256.	1.6	26
83	Expression of cortisol metabolism-related genes shows circadian rhythmic patterns in human adipose tissue. International Journal of Obesity, 2009, 33, 473-480.	1.6	51
84	Mechanisms of obesity and related pathology: linking immune responses to metabolic stress. FEBS Journal, 2009, 276, 5747-5754.	2.2	115
85	Quantitative measurements of corticosteroids in ex vivo samples using on-line SPE-LC/MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 303-310.	1.2	16
86	The role and regulation of 11Î²-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Molecular and Cellular Endocrinology, 2009, 301, 123-131.	1.6	70
87	Effects of glucocorticoids on fat mass and the therapeutic potential of targeting 11Î²-hydroxysteroid dehydrogenase type 1 in obesity. Clinical Lipidology, 2009, 4, 439-447.	0.4	0
88	Is metabolic syndrome a mild form of Cushingâ€™s syndrome?. Reviews in Endocrine and Metabolic Disorders, 2010, 11, 141-145.	2.6	19
90	Emodin, a natural product, selectively inhibits 11Î²â€hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in dietâ€induced obese mice. British Journal of Pharmacology, 2010, 161, 113-126.	2.7	109
91	Estrogen Reduces 11Î²â€Hydroxysteroid Dehydrogenase Type 1 in Liver and Visceral, but Not Subcutaneous, Adipose Tissue in Rats. Obesity, 2010, 18, 470-475.	1.5	28
92	The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. Journal of Endocrinology, 2010, 204, 153-164.	1.2	106
93	â€œControlâ€laboratory rodents are metabolically morbid: Why it matters. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6127-6133.	3.3	317
94	Role of Heme Oxygenase in Inflammation, Insulin-Signalling, Diabetes and Obesity. Mediators of Inflammation, 2010, 2010, 1-18.	1.4	129

#	Article	IF	Citations
95	Weight Loss after Gastric Bypass Surgery in Women Is Followed by a Metabolically Favorable Decrease in 11Î²-Hydroxysteroid Dehydrogenase 1 Expression in Subcutaneous Adipose Tissue. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3527-3531.	1.8	19
96	11Î²-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs, 2010, 19, 1067-1076.	1.9	44
97	Role of glucocorticoids and the glucocorticoid receptor in metabolism: Insights from genetic manipulations. Journal of Steroid Biochemistry and Molecular Biology, 2010, 122, 10-20.	1.2	97
98	Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue. Journal of Steroid Biochemistry and Molecular Biology, 2010, 122, 28-34.	1.2	53
99	Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. Journal of Steroid Biochemistry and Molecular Biology, 2010, 122, 21-27.	1.2	75
100	Obesity and corticosteroids: 11Î²-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Molecular and Cellular Endocrinology, 2010, 316, 154-164.	1.6	150
101	Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Molecular and Cellular Endocrinology, 2010, 315, 292-298.	1.6	14
102	Cortisol response to the Trier Social Stress Test in obese and reduced obese individuals. Biological Psychology, 2010, 84, 325-329.	1.1	25
103	Differences in associations between HSD11B1 gene expression and metabolic parameters in subjects with and without impaired glucose homeostasis. Diabetes Research and Clinical Practice, 2010, 88, 252-258.	1.1	8
106	Adipocyte Development and Experimental Obesity. Growth Hormone, 2011, , 321-352.	0.2	1
107	Expression of 11Î²-hydroxysteroid dehydrogenase type 1 in visceral and subcutaneous adipose tissues of patients with polycystic ovary syndrome is associated with adiposity. Journal of Steroid Biochemistry and Molecular Biology, 2011, 123, 127-132.	1.2	19
108	Adipose tissue-targeted 11.BETA.-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity. Endocrine Journal, 2011, 58, 199-209.	0.7	20
109	11Î²-Hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progress. Frontiers in Neuroendocrinology, 2011, 32, 265-286.	2.5	201
110	Metabolic gene expression changes in the hippocampus of obese epileptic male rats in the pilocarpine model of temporal lobe epilepsy. Brain Research, 2011, 1426, 86-95.	1.1	11
111	Steroid metabolism and excretion in severe anorexia nervosa: effects of refeeding. American Journal of Clinical Nutrition, 2011, 93, 911-917.	2.2	21
112	Recycling Between Cortisol and Cortisone in Human Splanchnic, Subcutaneous Adipose, and Skeletal Muscle Tissues In Vivo. Diabetes, 2012, 61, 1357-1364.	0.3	57
113	Adipokines and Cardiovascular Risk in Cushingâ€™s Syndrome. Neuroendocrinology, 2012, 95, 187-206.	1.2	47
114	11Î²-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome. Pharmacological Reports, 2012, 64, 1055-1065.	1.5	26

#	Article	IF	Citations
115	Contribution of glucocorticoidâ€“mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. Biochemical and Biophysical Research Communications, 2012, 419, 182-187.	1.0	65
116	The role of mediastinal adipose tissue 11Î²-hydroxysteroid d ehydrogenase type 1 and glucocorticoid expression in the development of coronary atherosclerosis in obese patients with ischemic heart disease. Cardiovascular Diabetology, 2012, 11, 115.	2.7	18
117	Tissue-Specific Effects of Loss of Estrogen during Menopause and Aging. Frontiers in Endocrinology, 2012, 3, 19.	1.5	82
118	Adipose tissue development and its potential contribution to later obesity. , 0, , 124-134.		0
119	Tissue-specific modulation of mineralocorticoid receptor function by 11Î²-hydroxysteroid dehydrogenases: An overview. Molecular and Cellular Endocrinology, 2012, 350, 168-186.	1.6	134
120	Liver Upregulation of Genes Involved in Cortisol Production and Action Is Associated with Metabolic Syndrome in Morbidly Obese Patients. Obesity Surgery, 2012, 22, 478-486.	1.1	30
121	Induction of 11Î²-HSD 1 and Activation of Distinct Mineralocorticoid Receptor- and Glucocorticoid Receptor-Dependent Gene Networks in Decidualizing Human Endometrial Stromal Cells. Molecular Endocrinology, 2013, 27, 192-202.	3.7	74
122	11Î²-Hydroxysteroid Dehydrogenases: Intracellular Gate-Keepers of Tissue Glucocorticoid Action. Physiological Reviews, 2013, 93, 1139-1206.	13.1	659
123	11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. Metabolism: Clinical and Experimental, 2013, 62, 21-33.	1.5	87
124	Herbal approaches to system dysfunctions. , 2013, , 183-350.		0
125	Mediastinal adipose tissue expresses a pathogenic profile of 11 Î²-hydroxysteroid dehydrogenase Type 1, glucocorticoid receptor, and CD68 in patients with coronary artery disease. Cardiovascular Pathology, 2013, 22, 183-188.	0.7	9
126	Pathophysiology of Human Visceral Obesity: An Update. Physiological Reviews, 2013, 93, 359-404.	13.1	1,751
127	11Î²-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. Endocrine Reviews, 2013, 34, 525-555.	8.9	152
128	Differences between men and women in the regulation of adipose 11Î²-HSD1 and in its association with adiposity and insulin resistance. Diabetes, Obesity and Metabolism, 2013, 15, 1056-1060.	2.2	8
129	Steroid Metabolism and Excretion in Anorexia Nervosa. Vitamins and Hormones, 2013, 92, 125-140.	0.7	11
130	The role and regulation of 11Î²-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Hormone Molecular Biology and Clinical Investigation, 2013, 15, 37-48.	0.3	26
131	Stress and Its Effects on Glucose Metabolism and 11-HSD Activities in Rats Fed on a Combination of High-Fat and High-Sucrose Diet with Glycyrrhizic Acid. Journal of Diabetes Research, 2013, 2013, 1-18.	1.0	15
132	Increased Visceral Adiposity and Cortisol to Cortisone Ratio in Adults With Congenital Lifetime Isolated GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3285-3289.	1.8	28

#	Article	IF	Citations
133	The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes. International Journal of Endocrinology, 2014, 2014, 1-26.	0.6	72
134	Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk. Hormone Molecular Biology and Clinical Investigation, 2014, 19, 75-88.	0.3	37
135	Mechanisms of Glucocorticoid-Induced Insulin Resistance. Endocrinology and Metabolism Clinics of North America, 2014, 43, 75-102.	1.2	264
136	The Postprandial Rise in Plasma Cortisol in Men Is Mediated by Macronutrient-Specific Stimulation of Adrenal and Extra-Adrenal Cortisol Production. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 160-168.	1.8	56
137	The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytes. International Journal of Obesity, 2014, 38, 1228-1233.	1.6	75
138	Dietary fructose-related adiposity and glucocorticoid receptor function in visceral adipose tissue of female rats. European Journal of Nutrition, 2014, 53, 1409-1420.	1.8	23
139	Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 473-481.	1.8	265
140	Glycyrrhizic Acid as the Modulator of 11Î² -hydroxysteroid dehydrogenase (Type 1 and 2) in Rats under Different Physiological Conditions in Relation to the Metabolic Syndrome. Journal of Diabetes & Metabolism, 2015, 06, .	0.2	1
141	Association of HSD11B1 polymorphic variants and adipose tissue gene expression with metabolic syndrome, obesity and type 2 diabetes mellitus: a systematic review. Diabetology and Metabolic Syndrome, 2015, 7, 38.	1.2	23
142	Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E435-E449.	1.8	91
143	Tissue Specific Regulation of Glucocorticoids in Severe Obesity and the Response to Significant Weight Loss Following Bariatric Surgery (BARICORT). Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1434-1444.	1.8	35
144	Hypothalamic-pituitary-adrenal axis dysregulation and cortisol activity in obesity: A systematic review. Psychoneuroendocrinology, 2015, 62, 301-318.	1.3	297
145	Pioglitazone in adult rats reverses immediate postnatal overfeeding-induced metabolic, hormonal, and inflammatory alterations. Endocrine, 2015, 50, 608-619.	1.1	3
146	Updated survey of the steroid-converting enzymes in human adipose tissues. Journal of Steroid Biochemistry and Molecular Biology, 2015, 147, 56-69.	1.2	57
147	Diet-induced weight loss has chronic tissue-specific effects on glucocorticoid metabolism in overweight postmenopausal women. International Journal of Obesity, 2015, 39, 814-819.	1.6	29
148	Serum Cortisol-to-Cortisone Ratio and Blood Pressure in Severe Obesity before and after Weight Loss. CardioRenal Medicine, 2016, 6, 1-7.	0.7	7
149	In Obesity, HPA Axis Activity Does Not Increase with BMI, but Declines with Aging: A Meta-Analysis of Clinical Studies. PLoS ONE, 2016, 11, e0166842.	1.1	17
150	Regulation of 11Î²-hydroxysteroid dehydrogenase type 1 following caloric restriction and re-feeding is species dependent. Chemico-Biological Interactions, 2017, 276, 95-104.	1.7	3

#	Article	IF	Citations
151	Cortisol Metabolism as a Regulator of the Tissue-Specific Glucocorticoid Action. , 2017, , 271-301.		0
152	11Î²-Hydroxysteroid Dehydrogenases and Hypertension in the Metabolic Syndrome. Current Hypertension Reports, 2017, 19, 100.	1.5	34
153	Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and HFD-Induced Obesity and Impairs the Feeding-Fasting Transition. Diabetes, 2017, 66, 272-286.	0.3	53
154	Dietary and Hormonal Factors Involved in Healthy or Unhealthy Visceral Adipose Tissue Expansion. , 2017, , .		0
155	Alterations of Cortisol Metabolism in Human Disorders. Hormone Research in Paediatrics, 2018, 89, 320-330.	0.8	20
156	Impact of MR on mature adipocytes in high-fat/high-sucrose diet-induced obesity. Journal of Endocrinology, 2018, 239, 63-71.	1.2	13
158	Glucocorticoid-induced insulin resistance is related to macrophage visceral adipose tissue infiltration. Journal of Steroid Biochemistry and Molecular Biology, 2019, 185, 150-162.	1.2	25
159	Regulation of alternative splicing in obesity-induced hypertension . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1597-1615.	1.1	9
160	Expression and activity of the cortisol-activating enzyme 11Î²-hydroxysteroid dehydrogenase type 1 is tissue and species-specific. Chemico-Biological Interactions, 2019, 303, 57-61.	1.7	18
161	Environmental Factors Associated with Physical Activity and Screen Time Among Children With and Without Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 2020, 50, 1572-1579.	1.7	30
162	Changes of BMI, steroid metabolome and psychopathology in patients with anorexia nervosa during hospitalization. Steroids, 2020, 153, 108523.	0.8	7
163	Early weaning leads to specific glucocorticoid signalling in fat depots of adult rats. Endocrine, 2020, 67, 180-189.	1.1	3
164	Stress, glucocorticoid signaling pathway, and metabolic disorders. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1273-1280.	1.8	10
165	Glucocorticoid Metabolism in Obesity and Following Weight Loss. Frontiers in Endocrinology, 2020, 11, 59.	1.5	56
166	The mineralocorticoid receptorâ€"an emerging player in metabolic syndrome?. Journal of Human Hypertension, 2021, 35, 117-123.	1.0	20
167	The Impact of Epigallocatechin Gallate and Coconut Oil Treatment on Cortisol Activity and Depression in Multiple Sclerosis Patients. Life, 2021, 11, 353.	1.1	11
168	Stress, Hormones, and Metabolism. , 2022, , 502-509.		0
169	The Role of Environmental Obesogens in the Obesity Epidemic. Growth Hormone, 2011, , 383-399.	0.2	7

#	Article	IF	Citations
170	Early Origins of Obesity and Developmental Regulation of Adiposity. , 2012, , 379-408.		2
171	Sex Differences in Body Fat Distribution. , 2012, , 123-166.		8
172	Association between 11Î²-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome. Biochemia Medica, 0, , 76-85.	1.2	14
173	Effects of Proportions of Dietary Macronutrients on Glucocorticoid Metabolism in Diet-Induced Obesity in Rats. PLoS ONE, 2010, 5, e8779.	1.1	9
174	Skeletal Muscle 11beta-HSD1 Controls Glucocorticoid-Induced Proteolysis and Expression of E3 Ubiquitin Ligases Atrogin-1 and MuRF-1. PLoS ONE, 2011, 6, e16674.	1.1	39
175	Obesity and Insulin Resistance in Childhood and Adolescence. , 2005, , 293-319.		1
176	Upregulation of Adipose 11-Î²-Hydroxysteroid Dehydrogenase Type 1 Expression in Ovariectomized Rats Is due to Obesity Rather Than Lack of Estrogen. Obesity, 0, , .	1.5	0
177	Glucocorticoids as Modulators of Adipose Inflammation. Oxidative Stress and Disease, 2009, , 127-148.	0.3	0
178	Hepatic Carbohydrate Metabolism. Molecular Pathology Library, 2011, , 109-123.	0.1	0
179	Gamete/Embryo-Fetal Origins of Obesity. , 2014, , 137-156.		0
180	Corticosteroid Receptors, Their Chaperones and Cochaperones: How Do They Modulate Adipogenesis?. Nuclear Receptor Research, 2014, 1, .	2.5	1
181	11Î²-Hydroxysteroid Dehydrogenase Type 1 is not Overexpressed in Cushingâ€™s Syndrome Adipose Depots. Journal of Diabetes, Metabolic Disorders & Control, 2014, 1, .	0.2	0
182	Early Origins of Obesity and Developmental Regulation of Adiposity. , 2017, , 427-456.		0
183	Sex Differences in Body Fat Distribution. , 2017, , 257-300.		3
184	Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population. Biochemia Medica, 2012, 22, 76-85.	1.2	6
185	Effects of very low-calorie ketogenic diet on hypothalamicâ€“pituitaryâ€“adrenal axis and reninâ€“angiotensinâ€“aldosterone system. Journal of Endocrinological Investigation, 2023, 46, 1509-1520.	1.8	8